Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant - PubMed
7 days ago
- #multiple myeloma
- #risk stratification
- #stem cell transplant
- Validation of the 2025 IMS/IMWG risk classification in newly diagnosed multiple myeloma (NDMM) patients treated with quadruplet therapy (QUAD) and autologous stem cell transplantation (ASCT).
- The new IMS/IMWG high-risk (new-HiR) criteria combine cytogenetic abnormalities, next-generation sequencing data, β2 microglobulin, and renal function.
- Among 310 patients, 29% were classified as new-HiR, showing worse progression-free survival (PFS) and overall survival (OS) compared to old-HiR criteria.
- The new criteria better fit predictive models for PFS and OS and identified misclassified patients under the old criteria.
- The 2025 IMWG/IMS criteria outperform legacy risk classification systems in identifying high-risk patients despite modern therapy.